| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
3,367 |
3,276 |
$216K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,274 |
2,222 |
$54K |
| 80053 |
Comprehensive metabolic panel |
4,915 |
4,717 |
$38K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,653 |
1,601 |
$32K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,433 |
1,422 |
$32K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,429 |
1,418 |
$32K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,456 |
2,428 |
$28K |
| 80061 |
Lipid panel |
2,901 |
2,888 |
$28K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,290 |
1,282 |
$26K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
4,452 |
4,123 |
$24K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,147 |
2,122 |
$14K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
695 |
695 |
$12K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,227 |
1,190 |
$6K |
| 84439 |
|
843 |
830 |
$5K |
| 82607 |
|
439 |
439 |
$5K |
| 85027 |
|
984 |
978 |
$5K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
96 |
93 |
$4K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
164 |
164 |
$4K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
204 |
204 |
$3K |
| 82570 |
|
895 |
882 |
$3K |
| 82043 |
|
723 |
721 |
$3K |
| 86780 |
|
228 |
228 |
$2K |
| 86803 |
|
195 |
195 |
$2K |
| 82728 |
|
164 |
157 |
$2K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
13 |
13 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
4,747 |
4,311 |
$1K |
| 83540 |
|
228 |
225 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
174 |
148 |
$950.04 |
| 87340 |
|
129 |
129 |
$864.52 |
| 83550 |
|
136 |
135 |
$811.63 |
| 87510 |
|
43 |
43 |
$566.26 |
| 87480 |
|
43 |
43 |
$566.26 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
12 |
12 |
$500.87 |
| 87660 |
|
43 |
43 |
$486.10 |
| 87077 |
|
65 |
64 |
$389.64 |
| 86762 |
|
39 |
39 |
$339.89 |
| 87807 |
|
40 |
40 |
$328.69 |
| 87150 |
|
12 |
12 |
$307.86 |
| 86140 |
|
87 |
76 |
$296.75 |
| 86850 |
|
40 |
40 |
$232.33 |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
13 |
13 |
$143.33 |
| 81001 |
|
42 |
36 |
$90.85 |
| 82950 |
|
26 |
26 |
$90.26 |
| 86901 |
|
40 |
40 |
$68.40 |
| 86900 |
|
40 |
40 |
$68.40 |
| 87081 |
|
12 |
12 |
$58.20 |